Cardiovascular Disease Archives - Psychiatry Advisor

General Medicine

Early Glycemic Control May Improve CV Outcomes in Patients With T2D

May 19, 2022

Early control of glycated hemoglobin (HbA1c) may improve cardiovascular outcomes in type 2 diabetes.

General Psychiatry

Psychiatric Disorders Associated With Similar Risk as Other Comorbidities in Breakthrough COVID-19 Infections

By

Jessica Nye, PhD

May 6, 2022

Investigators at the San Francisco Veterans Affairs (VA) Health Care System evaluated VA health records between February 2020 and November 2021.

Child/Adolescent Psychiatry

Childhood Abuse Associated With CVD Risk Factors Varied by Race, Sex

May 3, 2022

The associations between exposure to abuse in childhood and risk factors for incident cardiovascular disease vary by race and sex.

Neurocognitive Disorders

Subjective Cognitive Impairment Associated With Major Adverse CV Events in Patients With T2D

April 29, 2022

For individuals with type 2 diabetes, subjective cognitive impairment (SCI) is associated with cardiovascular events.

General Psychiatry

CVD, Mortality Highly Identified With Serious Mental Illness

April 26, 2022

People with serious mental illness (SMI), particularly schizophrenia, have higher levels of cardiovascular disease (CVD)-related mortality and a higher incidence of CVD than the general population.

Geriatric Psychiatry

Cardiovascular Risk Factors Associated With Increased Depression Risk in Older Adults

April 22, 2022

Cardiovascular risk factors are associated with an increased risk for depression in older adults.

Sleep-Wake Disorders

Understanding the Cardiovascular Burden Among Patients With Narcolepsy

By

Jessica Nye

April 12, 2022

Presenting at the 2022 AAN Annual Meeting, researchers evaluated the overall cardiovascular burden among adult patients with narcolepsy.

Tobacco-Use Disorder

Benefits of Smoking Cessation Quantified in Patients With Atherosclerotic CVD

April 12, 2022

For patients with established atherosclerotic cardiovascular disease, the treatment benefit of smoking cessation is equivalent to the use of targeted pharmaceutical interventions in persistent smokers.